Radotinib to take on Gleevec, Sprycel

Published: 2012-01-06 06:58:00
Updated: 2012-01-06 06:58:00
Radotinib is Korea’s 18th homegrown leukemia drug and the world’s fifth and was approved by the Korea Food and Drug Administration on January 4.

Market watchers say the new drug is likely to bring a huge change to the anti-leukemia medicine market, as patients here have had access to only impo...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.